Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention

被引:16
作者
Boraz, MA
Simkin-Silverman, LR
Wing, RR
Meilahn, EN
Kuller, LH
机构
[1] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA
[2] Brown Univ, Dept Psychiat, Providence, RI 02912 USA
关键词
hormone therapy; menopause; cardiovascular; lifestyle intervention;
D O I
10.1006/pmed.2001.0858
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Background. The decision to take hormone replacement therapy (HRT) is a choice many women encounter when entering menopause. The purpose of this study was to examine the choice to take HRT while participating in a lifestyle intervention to reduce cardiovascular risk through the menopause. Methods. The Women's Healthy Lifestyle Project is a randomized clinical trial designed to examine whether a behavioral lifestyle intervention can decrease the expected rise in cardiovascular risk through the menopause. Participants (N = 535) completed questionnaires and were interviewed regarding menopausal symptoms, menopausal status, hot flashes, and HRT use at baseline and 54 months. Results. The intervention was successful in preventing risk elevation through the 54-month visit. At the final visit, there was no difference between the intervention and control groups in the percentage who had become postmenopausal (32.9% vs 35.0%, respectively), there was no difference between control and intervention with HRT use, with 31.2% reporting use of HRT, and there was no difference between groups with menopausal symptoms. The women started HRT an average of 6 months after they missed a period. Baseline risk factors did not predict HRT use at the 54-month visit. Conclusions. A sizable number of women reported HRT use. The decision to use HRT was not influenced by the lifestyle intervention or their baseline cardiovascular risk, and these women started HRT very early in the peri- to postmenopause. Further, weight loss in the perimenopause did not affect menopausal symptoms. (C) 2001 American Health Foundation and Academic Press.
引用
收藏
页码:108 / 114
页数:7
相关论文
共 25 条
[1]
BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062
[2]
Beral V, 1997, LANCET, V349, P1103, DOI 10.1016/S0140-6736(05)62328-8
[3]
Beral V, 1999, J Epidemiol Biostat, V4, P191
[4]
Adverse endometrial effects during long cycle hormone replacement therapy [J].
Bjarnason, K ;
Cerin, Å ;
Lindgren, R ;
Weber, T .
MATURITAS, 1999, 32 (03) :161-170
[5]
Brzezinski A, 1997, MENOPAUSE, V4, P89
[6]
LIFETIME RISKS OF HIP, COLLES, OR VERTEBRAL FRACTURE AND CORONARY HEART-DISEASE AMONG WHITE POSTMENOPAUSAL WOMEN [J].
CUMMINGS, SR ;
BLACK, DM ;
RUBIN, SM .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (11) :2445-2448
[7]
HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN [J].
GRADY, D ;
RUBIN, SM ;
PETITTI, DB ;
FOX, CS ;
BLACK, D ;
ETTINGER, B ;
ERNSTER, VL ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) :1016-1037
[8]
Drug therapy - Hormone replacement therapy in the aged - A state of the art review [J].
Jacobs, S ;
Hillard, TC .
DRUGS & AGING, 1996, 8 (03) :193-213
[9]
Kuller Lewis H., 1994, Annals of Epidemiology, V4, P119, DOI 10.1016/1047-2797(94)90057-4